Home > Clinical Trials
Check All Search

Saved trials

COMPLETED
NCT01777503
The Elderly ACS II Trial
1,457 Enrollment(s)
2 Study location(s)
INTERVENTIONAL (PHASE4)
Acute Coronary Syndrome


Coronary Arteriosclerosis


Myocardial Ischemia


Cardiovascular Diseases
RECRUITING
NCT07030569
RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study
500 Enrollment(s)
1 Study location(s)
OBSERVATIONAL (None)
Radiomic


Radiomics


Breast Cancer Metastatic


Breast Cancer Stage IV


Breast Carcinoma


Breast Neoplasms


Breast Cancer


Breast Cancer With Bone Metastasis


Breast Cancer With Metastatic Bone Disease


Trastuzumab


HER2


HER2 + Breast Cancer


HER2 Positive Breast Carcinoma


HER2-positive Breast Cancer


Her2/Neu Positive Advanced Solid Tumors


HER2/Neu-positive Breast Cancer
NOT_YET_RECRUITING
NCT07012031
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
37 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
Locally Advanced Lung Non-Small Cell Carcinoma


Metastatic Lung Non-Small Cell Carcinoma


Stage III Lung Cancer AJCC v8


Stage IV Lung Cancer AJCC v8
RECRUITING
NCT05993234
A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)
257 Enrollment(s)
68 Study location(s)
OBSERVATIONAL (None)
HER2-positive Advanced Gastric Cancer


HER2-positive Gastroesophageal Junction Adenocarcinoma
ACTIVE_NOT_RECRUITING
NCT04494425
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
866 Enrollment(s)
294 Study location(s)
INTERVENTIONAL (PHASE3)
Advanced or Metastatic Breast Cancer
NOT_YET_RECRUITING
NCT07025148
Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2)
40 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE4)
Coronary Arterial Disease (CAD)


Percutaneous Coronary Intervention (PCI)
NOT_YET_RECRUITING
NCT07022483
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
710 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE3)
Endometrial Cancer
RECRUITING
NCT06832202
A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients
50 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE2)
HER2-low Hormone Receptor Positive Breast Cancer